Support for Small Business Innovation Research (SBIR) to Develop New Technologies for Development and Integration of Novel Components for Open and Closed Loop Hormone Replacement Platforms for T1D Therapy (R43/R44 Clinical Trial Not Allowed)

Funding Agency:
National Institutes of Health

This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications for funding to perform research leading to the development of new approaches to create devices/components with enhanced accuracy and less patient burden that will represent real advancements regarding safety and effectiveness of glucose control technologies and their integration into open and closed loop hormone replacement systems.


  • Letter of Intent Due Date: February 9, 2022 and September 7, 2022
  • Application Due Date(s): March 9, 2022 and October 7, 2022

RFA-DK-21-011 Expiration Date October 08, 2022

Agency Website

Eligibility Requirements

Only United States small business concerns (SBCs) are eligible to submit applications for this opportunity.

Amount Description

Budgets up to $300,000 total costs per project for Phase I and up to $2,000,000 total costs per project for Phase II may be requested.

Duration of up to 1 year for Phase I and up to 2 years for Phase II may be requested.

    Funding Type





    Engineering and Physical Sciences
    Medical - Clinical Science
    Medical - Translational

    External Deadline

    October 7, 2022